Construct of self-circularization RNA

The self-circulating RNA structure addresses instability issues in RNA therapies by using a Group I intron ribozyme for efficient circRNA production, ensuring stable and rapid expression of therapeutic RNAs and proteins.

KR102998554B1Active Publication Date: 2026-08-03RZNOMICS INC
1 Cites 0 Cited by

Patent Information

Application Number
KR1020230118503
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-09-06
Filing Date
2023-09-06
Publication Date
2026-08-03
Estimated Expiration
2043-09-06

AI Technical Summary

Technical Problem

Existing RNA therapies, such as mRNA, face challenges with instability and short half-life, while circular RNA (circRNA) offers stability but lacks efficient self-targeting and splicing capabilities.

Method used

A self-circulating RNA structure is designed with an internal guide sequence (IGS) forming a guanine (G):uracil (U) wobble base pair, using a Group I intron ribozyme for self-targeting and splicing reactions, enabling circularization without additional GTP treatment, and including features like P1 and P10 helices and antisense binding sequences for efficient circRNA production.

Benefits of technology

The self-circulating RNA structure achieves stable circRNA formation, allowing for rapid expression of functional RNAs like miRNA, mRNA vaccines, and proteins, with high stability and efficiency in cellular expression.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The self-circulating RNA structure of the present invention can be expressed in a DNA vector and simultaneously circularized through a self-targeting and splicing reaction to form circRNA, and the circRNA can be composed only of a target gene, and the target gene includes an IRES region, a start codon, and a stop codon, which has the advantage of enabling rapid expression of a peptide or protein.
Need to check novelty before this filing date? Find Prior Art